高级检索

早期肺腺癌组织中人天冬氨酸β-羟化酶、CD44V6的表达水平及临床意义

Expression levels and clinical significance of human aspartic acid β-hydroxylase and CD44V6 in early lung adenocarcinoma tissues

    摘要
  • 摘要:
    目的 观察早期肺腺癌组织中人天冬氨酸β-羟化酶(ASPH)、CD44V6的表达情况, 并分析其与临床病理特征及预后的关系。
    方法 选取2016年10月-2022年6月烟台业达医院行手术治疗且完成3年随访的120例早期肺腺癌患者的癌组织标本, 并根据组织分化程度另取配对的30例早期肺腺癌患者癌旁组织标本为对照。采用免疫组织化学法检测癌组织及癌旁组织中ASPH、CD44V6的表达情况。
    结果 癌组织中ASPH、CD44V6阳性率均高于癌旁组织, 差异有统计学意义(P < 0.05)。临床分期为ⅠB期、分化程度为低分化的早期肺腺癌患者癌组织中ASPH阳性表达率高于临床分期为ⅠA期、分化程度为中高分化的癌组织, 差异有统计学意义(P < 0.05); 年龄≥ 60岁、临床分期为ⅠB期、分化程度为低分化的早期肺腺癌患者癌组织中CD44V6阳性表达率高于年龄 < 60岁、临床分期为ⅠA期、分化程度为中高分化的癌组织, 差异有统计学意义(P < 0.05)。经Somers'd检验结果显示, 临床分期、分化程度与ASPH表达呈正相关(d>0, P < 0.05); 年龄、临床分期、分化程度与CD44V6表达呈正相关(d>0, P < 0.05)。经卡方检验Phi系数显示, ASPH与CD44V6表达在早期肺腺癌中呈正相关(Phi=0.906, P < 0.05)。Logistic回归分析结果显示, ASPH与CD44V6阳性表达是早期肺腺癌患者预后不良的危险因素(OR>1, P < 0.05)。受试者工作特征(ROC)曲线显示, ASPH、CD44V6预测早期肺腺癌患者预后的敏感度分别为0.960、0.920, 特异度分别为0.284、0.242。
    结论 早期肺腺癌组织中ASPH和CD44V6阳性表达率高; 年龄、临床分期、分化程度与CD44V6阳性表达有关, 临床分期、分化程度与ASPH阳性表达有关; ASPH、CD44V6表达与早期肺腺癌患者预后情况有关。

     

    Abstract:
    Objective To observe the expression levels of human aspartic acid β-hydroxylase (ASPH) and CD44V6 in early lung adenocarcinoma tissues, and analyze their relationships with clinicopathological characteristics and prognosis.
    Methods A total of 120 cancer tissue samples from patients with surgical treatment for early lung adenocarcinoma and 3-year follow-up in the Yantai Yeda Hospital from October 2016 to June 2022 were selected, and 30 matched adjacent tissue samples from patients with early lung adenocarcinoma were selected as controls based on the degree of tissue differentiation. Immunohistochemical method was used to detect the expressions of ASPH and CD44V6 in cancer tissues and adjacent tissues.
    Results The positive rates of ASPH and CD44V6 in cancer tissues were significantly higher than those in adjacent tissues (P < 0.05). The positive expression rates of ASPH in early lung adenocarcinoma patients with stage ⅠB and low differentiation were significantly higher than those in patients with stage ⅠA and medium to high differentiation (P < 0.05). The positive expression rates of CD44V6 in early lung adenocarcinoma patients with age ≥ 60 years, clinical stage ⅠB and low differentiation were significantly higher than those in patients with age < 60 years, clinical stage Ⅰ A and medium to high differentiation (P < 0.05). The Somers'd test showed that the clinical stage and degree of differentiation were positively correlated with the expression of ASPH (d>0, P < 0.05); age, clinical stage and degree of differentiation were positively correlated with the expression of CD44V6 (d>0, P < 0.05). The Phi coefficient of the Chi square test showed that the expression of ASPH was positively correlated with expression of CD44V6 in early lung adenocarcinoma (Phi=0.906, P < 0.05).The Logistic regression analysis showed that the positive expressions of ASPH and CD44V6 were risk factors for poor prognosis in early lung adenocarcinoma patients (OR>1, P < 0.05). Receiver operator characteristic (ROC) curve showed that the sensitivities of ASPH and CD44V6 in predicting the prognosis of early lung adenocarcinoma patients were 0.960 and 0.920 respectively, and the specificities were 0.284 and 0.242 respectively.
    Conclusion The positive expression rates of ASPH and CD44V6 are high in early lung adenocarcinoma tissues; age, clinical stage and degree of differentiation are related with positive expression of CD44V6, while clinical stage and degree of differentiation are related with positive expression of ASPH; the expressions of ASPH and CD44V6 are related to the prognosis of early lung adenocarcinoma patients.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回